anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a cosmetic composition for alleviating acne skin, and a mask pack using the same, wherein the cosmetic composition can prevent or treat acne by opening pores closed by acne, promoting the secretion of sebum, and inhibiting the growth of acne bacteria. A cosmetic material is produced by dispersing several sorts of natural extracts, aqueous compositions, and acne treating functional additives in refined water. Not only makeup but also corneum and bodily waste in pores are cleanly removed, and skin troubles and skin irritation are minimized. Also, parched and dry skin can be softly and smoothly treated. A natural extract is included, so excessive sebum causing acne is actively discharged. Accordingly, the blocking of pores is prevented. At the same time, an antibacterial or anti-inflammatory effect with respect to acne bacteria is ensured, and the growth of acne bacteria can be controlled. Moreover, the growth of acne bacteria can be easily controlled or treated, and thus skin diseases such as acne can be fundamentally treated and removed. Thus, a skin improving effect can be enhanced.
A kit for comfortably collecting the scent of one person prolonging it and applying that scent elsewhere on the person or on another person is disclosed. In certain embodiments, the scent collected is the scent from an individual. In still other preferred embodiments, the scent collected is from a sexual partner and is applied elsewhere on that person's body or clothing or to the person's sexual partner. The scent can be collected by applying a collective lotion, which may be provided on a moistened pad, to a user's finger, an applicator or the like and touching or rubbing the desired region. Thereafter, the user's finger or the applicator can be used to apply the scent where desired, such as on their hair, shoulder, arm, chest, external skin area above the upper lip and underneath the nose, hand, wrist, neck, or the like, or on those areas of another desired person. A scent removed may also be provided to subsequently remove the scent transferred as desired.
New techniques have been developed and tested to expand the usefulness of minimally invasive spine surgery beyond disk herniation. This includes endoscopic electrothermic ablation which can be used to target SIJ-associated CLBP. A small retrospective study demonstrated significant improvements in Visual Analog Scale and Oswestry Disability Index from pre-operative levels in patients with CLBP associated with the SIJ for up to 21 months following the procedure. However, there has not yet been a prospective study to assess the efficacy of this procedure, and therefore, this is the aim of this study.
BACKGROUND AND OBJECTIVE: Federated learning (FL) is an emerging distributed learning framework allowing multiple clients (hospitals, institutions, smart devices, etc.) to collaboratively train a centralized machine learning model without disclosing personal data. It has the potential to address several healthcare challenges, including a lack of training data, data privacy, and security concerns. However, model learning under FL is affected by non-i.i.d. data, leading to severe model divergence and reduced performance due to the varying client's data distributions. To address this problem, we propose FedDSS, Federated Data Similarity Selection, a framework that uses a data-similarity approach to select clients, without compromising client data privacy.
METHODS: FedDSS comprises a statistical-based data similarity metric, a N-similar-neighbor network, and a network-based selection strategy. We assessed FedDSS' performance against FedAvg's in i.i.d. and non-i.i.d. settings with two public pediatric sepsis datasets (PICD and MIMICIII). Selection fairness was measured using entropy. Simulations were repeated five times to evaluate average loss, true positive rate (TPR), and entropy.
RESULTS: In i.i.d setting on PICD, FedDSS achieved a higher TPR starting from the 9th round and surpassing 0.6 three rounds earlier than FedAvg. On MIMICIII, FedDSS's loss decreases significantly from the 13th round, with TPR > 0.8 by the 2nd round, two rounds ahead of FedAvg (at the 4th round). In the non-i.i.d. setting, FedDSS achieved TPR > 0.7 by the 4th and > 0.8 by the 7th round, earlier than FedAvg (at the 5th and 11th rounds). In both settings, FedDSS showed reasonable fairness (entropy of 2.2 and 2.1).
CONCLUSION: We demonstrated that FedDSS contributes to improved learning in FL by achieving faster convergence, reaching the desired TPR with fewer communication rounds, and potentially enhancing sepsis prediction (TPR) over FedAvg.
Eight subjects in up to 8 cohorts will be dosed. A single subcutaneous injection of HTL0030310 or placebo will be administered. In each cohort, 6 subjects will receive HTL0030310 and 2 subjects will receive placebo.
Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
The present invention provides an atypical Aeromonas salmonicida inactivated vaccine composition of fish, wherein the atypical Aeromonas salmonicida inactivated vaccine composition comprises an inactivated mycobiont of a line derived from Sebastes schlegelii of atypical Aeromonas salmonicida. Provided is an Aeromonas salmonicida inactivated vaccine composition of fish, in which any one of subspecies, subsp. salmonicida, subsp. achromogenes, subsp. masoucida, subsp. smithia, or subsp. pectinolytica of Aeromonas salmonicida isolated from Aeromonas salmonicida having Aeromonas infectious diseases in a domestic fish farm is inactivated by formalin. Accordingly, furunculosis of which occurrence is increasing in domestic fish farms is prevented, and the composition can contribute to an increase in incomes of fishermen in fish farms.
No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets. The following information was obtained from the literature.

Adenosinergic agents (e.g., adenosine, regadenoson): Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A 2A-receptor agonist. The potential risk of cardiovascular side effects with intravenous adenosinergic agents may be increased during the testing period when dipyridamole is not held 48 hours prior to stress testing. 

Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
In this study, risk factors for coronary slow flow (CSF) patients were examined, and a clinical prediction model was created. This study involved 573 patients who underwent coronary angiography at our hospital because of chest pain from January 2020 to April 2022. They were divided into CSF group (249 cases) and noncoronary slow flow (NCF) group (324 cases) according to the coronary blood flow results. According to a 7:3 ratio, the patients were categorized into a training group consisting of 402 cases and a validation group consisting of 171 cases. The outcome was assessed by employing multiple logistic regression analysis to examine the factors that influenced it. The model's recognizability was assessed by calculating the consistency index and plotting the receiver operating characteristic curve. Its consistency was assessed by calibration curve, decision curve, and Hosmer-Lemeshow testing goodness-of-fit. The multivariate model included factors such as male, BMI, smoking, diabetes, ursolic acid, and high-density lipoprotein cholesterol. The model validation showed that the consistency index was 0.714, and the external validation set had a consistency index of 0.741. The areas under the curve for the training and external validation sets were respectively 0.730 (95% CI: 0.681-0.779) and 0.770 (95%CI: 0.699-0.841). Nomogram calibration curves indicated intense calibration, and the results of the Hosmer-Lemeshow goodness-of-fit test indicated that χ² = 1.118, P = .572. The nomogram combining various risk factors can be used for individualized predictions of CSF patients and then facilitate prompt and specific treatment.
Participants will receive a placebo orally BID for 12 weeks in Period 1. Participants will be re-randomized at Week 13 in a 1:1 ratio to receive LNK01001 Dose A orally BID for up to 24 weeks.
A method of processing drug alternatives for a selected drug. The method includes receiving a selection of the selected drug and generating a drug alternatives list from source data, the drug alternative list including a plurality of drug alternatives. The method includes gaining access to a price model and at least one price data source. The method includes determining respective prices for the plurality of drug alternatives according to the price model and the at least one price data source and ranking the plurality of drug alternatives in the drug alternatives list according to respective ordinality and respective prices. The method includes suppressing ones of the plurality of drug alternatives lacking a desired clinical outcome from the drug alternatives list. The method includes filtering resultant drug alternatives by at least one parameter. The method includes transmitting the drug alternatives list to a user computing system for display.
This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, methylergonovine maleate should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided.

Caution should be exercised in the presence of impaired hepatic or renal function.
The purpose of this study is to compare usual care against a group advanced care planning intervention comprised of two sessions led by trained community health workers or health educators from VA Palo Alto. A total of 50 participants will be randomly assigned to either usual care (n=25) or usual care + group advanced care planning intervention (n=25). Those in usual care will be mailed some educational materials about advanced care planning that they may review independently. Those in the group advanced care planning arm will participate in two 1-hour educational sessions led by the community health worker/educator that will be on site, by VA-approved video conference, or a hybrid model. Topics will include an introduction to advanced care planning, goals of care topics, advance directives, and physicians order of life sustaining treatment. Both usual care and the group advanced care planning arms will also participate in pre/post surveys and/or interviews.
Polygenic risk scores (PRS) have shown successes in clinics, but most PRS methods focus only on participants with distinct primary continental ancestry without accommodating recently-admixed individuals with mosaic continental ancestry backgrounds for different segments of their genomes. Here, we develop GAUDI, a novel penalized-regression-based method specifically designed for admixed individuals. GAUDI explicitly models ancestry-differential effects while borrowing information across segments with shared ancestry in admixed genomes. We demonstrate marked advantages of GAUDI over other methods through comprehensive simulation and real data analyses for traits with associated variants exhibiting ancestral-differential effects. Leveraging data from the Women's Health Initiative study, we show that GAUDI improves PRS prediction of white blood cell count and C-reactive protein in African Americans by > 64% compared to alternative methods, and even outperforms PRS-CSx with large European GWAS for some scenarios. We believe GAUDI will be a valuable tool to mitigate disparities in PRS performance in admixed individuals.
The method and system determine and report measures of adherence of patients to prescription medication regimens based upon fill gaps in the prescription history of the patients. The measure of adherence may be the proportion of days covered by the medication. The method and system may receive or access information relating to a patient's medical history, including past prescription medication fills. Fills of both the prescription medication and other medications that may substitute for the prescription medication may be considered in determining patient adherence levels. Upon determining the patient's level of adherence, the system and method may generate a report including the adherence information and associated information, such as a home pharmacy location. The report may include an indication of whether new-to-therapy information should be presented to a patient based on patient adherence levels.
The invention discloses a multi-core shell-sharing composite drug-loaded microsphere and a preparation method and application thereof. The particle size of the prepared FNS/PHBV @ PVA/CS drug-loaded microsphere meets the requirement of prostate targeted embolization treatment. From the drug release profile, it is known that no burst and sustained release occurs throughout the drug release process. In vitro cell experiments and hemolysis experiments prove that the medicine has good cell compatibility and blood compatibility. Experiments of rabbit ear embolism preliminarily show that the rabbit ear embolism has good embolism effect and good histocompatibility. And the preparation process is simple, the particle size is controllable, and the method is suitable for batch industrial production. The invention effectively combines the physical embolism performance and the drug slow-release performance of the composite drug-carrying microsphere, and has potential application prospect in the embolism treatment of BPH.
In view of the safety concerns of probiotics, more and more attention is paid to the beneficial effects of dead probiotics cells. Herein, we investigated and compared the alleviation effects of viable Bifidobacterium longum subsp. infantis B8762 (B. infantis B8762) and its heat-killed cells on dextran sodium sulfate (DSS)-induced inflammatory bowel disease (IBD) rats. Four groups of rats (n = 12 per group) were included: normal control, DSS-induced colitis rats without bacterial administration (DSS), DSS-induced colitis rats with viable B. infantis B8762 administration (VB8762), and DSS-induced colitis rats with dead B. infantis B8762 administration (DB8762). Our results showed that both VB8762 and DB8762 administration exerted significant protective effects on DSS-induced IBD rats, as evidenced by a reduction in mortality, disease activity index score, body weight loss, as well as decreased histology score, which were companied by a significant decrease in serum pro-inflammatory factors compared with DSS group, and a stronger effect on modulating the fecal microbiota alpha-diversity and beta-diversity compared with DSS group. Additionally, the fecal metabolome results showed that both VB8762 and DB8762 interventions indeed altered the fecal metabolome profile and related metabolic pathways of DSS-induced IBD rats. Therefore, given the alleviation effects on colitis, the DB8762 can be confirmed to be a postbiotic. Overall, our findings suggested that VB8762 and DB8762 had similar ability to alleviate IBD although with some differences. Due to the minimal safety concern of postbiotics, we propose that the postbiotic DB8762 could be a promising alternative to probiotics to be applied in the prevention and treatment of IBDs.IMPORTANCEInflammatory bowel disease (IBD) has emerged as a global disease because of the worldwide spread of western diets and lifestyles during industrialization. Up to now, many probiotic strains are used as a modulator of gut microbiota or an enhancer of gut barrier to alleviate or cure IBD. However, there are still many issues of using probiotics, which were needed to be concerned about, for instance, safety issues in certain groups like neonates and vulnerable populations, and the functional differences between viable and dead microorganisms. Therefore, it is of interest to investigate the beneficial effects of dead probiotics cells. The present study proved that both viable Bifidobacterium longum subsp. infantis B8762 and heat-killed cells could alleviate dextran sodium sulfate-induced colitis in rats. The findings help to support that some heat-killed probiotics cells can also exert relevant biological functions and can be used as a postbiotic.
Bisphenol A (BPA) exposure during pregnancy is known to predispose offspring to obesity in later life. Our previous studies demonstrated obesogenic effects in BPA-exposed offspring, including excess body fat, increased feed efficiency, adipocyte hypertrophy, and altered leptin signaling. However, the role of the placenta in mediating these effects remained unclear. This study investigates the mechanisms by which BPA exposure affects placental glucose and lipid transporters and their impact on offspring adiposity in Wistar rats. Dams were orally gavaged with BPA [0.4 (low dose-LD) and 4.0 (high dose-HD) μg/kg body weight] from gestational day (gD) 4-14. Gestational exposure to LD BPA increased the expression of 11β hydroxysteroid dehydrogenase 1 (11β HSD1) and estrogen receptor alpha (ERα) proteins (p<0.05) in the placenta compared to control and HD BPA. Similar changes were observed in the expression of mTOR signaling mediators, fatty acid transporters, and intracellular fatty acid-binding proteins. There were no changes in the dam's body weight or lipid and glucose profiles. However, there was a dose dependent increase in glucose transporter (GLUT1) expression in the placenta. While LD BPA increased hexokinase 2 expression in the placenta, HD BPA had no effect. Both doses of BPA increased IL6 expression, but only LD BPA exposure increased PPAR-gamma expression. Additionally, BPA exposure induced ADRP expression and localization, suggesting potential lipid overload in the placenta. Furthermore, BPA exposure altered the placental epigenetic profile, with increased expression of DNA methyltransferases (DNMTs). Overall, gestational BPA exposure led to dose-specific alterations in placental glucose and lipid metabolic activities, possibly playing an role in increasing the supply of these macronutrients to the fetus and predisposing the offspring to obesity.
Knee osteoarthritis (OA) is a common joint disease and a leading cause of pain and physical disability in older people. Its symptoms, including pain and physical disability, significantly affect patient's quality of life, and increased depression has been observed in patients with greater pain due to knee OA. Current management options include exercise, weight reduction, Non-steroidal anti-inflammatory drugs (NSAIDs) and other pain medication, intra-articular injections of steroid or hyaluronan, arthroscopic surgery and joint replacement. Except exercise and weight reduction, no known interventions have shown definitive evidence of benefits and safety for knee OA. Thus, it is still worth exploring effective and safe management options for knee OA patients.

Moxibustion is one of traditional Asian medicine using the heat stimulation by burning mugwort (mainly Artemisia vulgaris or Artemisia argyi) on acupuncture points, and regarded as a subtype of acupuncture. Previous literatures reported its use on chronic conditions including gastrointestinal disease, hypertension, musculoskeletal pain, cancer care, gynecological conditions and stroke rehabilitation solely or in combination with routine care or other traditional medicine. However, studies adequately evaluating effects and safety of moxibustion for patients with knee OA are insufficient. Given the gaps between little evidence for effects and safety of moxibustion for knee osteoarthritis and its wide use in clinical practice, the investigators attempted to assess the feasibility, effectiveness and safety of moxibustion for patients with knee osteoarthritis.
The intervention group comprises \~4800 patients born 1959-1988, living in the municipalities of Haderslev or Middelfart, and affiliated to one of the participating GPs. No control group is included.
The investigators propose to add an object-finding feature to a retinal prosthesis system. To use this feature, the participant will enable a special mode and input the desired object from a set of pre-programmed object types. Imagery from the visible light camera in the system eyeglasses will be processed using object recognition software as the participant scans their head across the room scene. When the object is identified in the scene by the processor, a flashing icon will be output to the epiretinal array in the appropriate position to guide the participant to the physical location of the object. Once located, the system will track the location of the object.

There will be two phases to the human subjects evaluation, each run initially through simulations in sighted human subjects, followed by tests in Argus II participants. In phase 1, system evaluation in human subjects at Johns Hopkins UNiversity (JHU) will explore performance in representative tasks and compare prosthetic visual performance without and with the new object finding feature. An important aspect of the evaluation will be the comparison of different icons and presentation modes to assist participants in locating and reaching objects. In phase 2, the system will be integrated into the Argus II video processing unit (VPU), and JHU will conduct human trials that include functional testing of the integrated prototype in representative environments and optimizing the ergonomics of the system, e.g. simultaneous finding and tracking of multiple objects/icons.
Stroke is the second leading cause of death and the third leading cause of death and disability combined in the world. The remote ischemic preconditioning (RIC) procedure is low-cost with excellent properties of safety, tolerability and feasibility in both AIS and cardiovascular diseases. In this study, we aim to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology. The RICAS study is a prospective, randomized, blind endpoint, multicenter study. Eligible patients with ischemic stroke of anterior circulation with large artery atherosclerosis etiology, poor collateral compensation, and more than 1 month of the symptom onset, are randomly assigned into the experimental group and control group with a ratio of 1:1. The patients in experiment group will receive treatment with RIC for 1 year as an adjunct to guideline-based treatment, while patients in control group only receive guideline-based treatment. The primary outcome is proportion of collateral status improvement, which is defined as an increase of ASITN/SIR score of 1 or more assessed on DSA at 12 months after randomization. The safety outcomes include RIC-related adverse events. A maximum of 300 patients (150 participants per group) are required to test the superiority hypothesis with 80% power (using a two-sided α = 0.05) to detect the 15% difference. The primary endpoint will further be stratified by age, gender, inclusion event (acute ischemic stroke ore transient ischemic stroke), tandem lesion, history of hypertension, hypercholesterolemia, diabetes mellitus, ischemic stroke, transient ischemic attack, and myocardial infarction. This study will provide the direct evidence for improvement of collateral status by chronic RIC treatment.